Calidi Posts $3.6M Q3 Loss, Cuts 39% of G&A, Executes $3M Restructuring to Extend Runway
CLDI is trading near its 52-week low of $0.62 (0.3% above the low) on light trading volume (0.3× avg).
Summary
Calidi reported a $3.6 million third-quarter net loss and $3.9 million of cash, then executed a November 6 restructuring expected to save $3 million a year to extend its runway while CLD-401 remains in IND-enabling studies.
Key Events · Earnings and Guidance · CLDI
-
Q3 Net Loss Narrows to $3.6M
Third-quarter 2026 net loss attributable to common stockholders was $3.6 million, down from $10.8 million in Q3 2025, a prior-year figure that included a $5.7 million non-cash deemed dividend on warrants; no such charge occurred this quarter.
-
Cash Falls to $3.9M
As of September 30, 2026, cash stood at $3.9 million plus $0.2 million restricted, down from $5.6 million in cash at December 31, 2025 — roughly one quarter of the reported $3.6 million net loss.
-
$3M Restructuring Executed November 6
A restructuring plan, predominantly headcount reductions, is expected to save $3 million on an annualized basis, extending the operating runway and preserving capital while the company pursues additional financing.
-
Cost Cuts: G&A Down 39%
General and administrative expenses fell $1.0 million, or 39%, in Q3 2026 versus the prior-year period, and $3.6 million, or 42%, over the nine months ended September 30, 2026.
Analysis · CLDI · Life Sciences
With $3.9 million in cash at the end of September against a $3.6 million quarterly net loss, the November 6 restructuring — mainly headcount cuts expected to save $3 million a year — reads as a survival move rather than a growth initiative. September's at-the-market registered direct offering brought in just $1.2 million, a thin raise for a clinical-stage biotech. Cost discipline is the offsetting positive: G&A fell 39% in the quarter and 42% year-to-date, and the net loss narrowed sharply from $10.8 million a year ago, a figure that included a $5.7 million non-cash deemed dividend on warrants. CLD-401 remains in IND-enabling studies, with a stated plan to dose the first patient in the second half of 2027, so the cash runway must stretch a long way before any clinical readout.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLDI was trading at $0.62 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.62 to $24.96. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.